NCT05979389View on ClinicalTrials.gov

Bicalutamide Therapy in Young Women With NAFLD and PCOS

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
NAFLDPCOS
Interventions
DRUG

Bicalutamide 50 mg

Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg

DRUG

Placebo

Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.

Trial Locations (1)

94143

RECRUITING

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of California, San Francisco

OTHER